Andere Sprachen Akebia Therapeutics, Inc.

Aktien

A1XF0S

US00972D1054

AKBA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.06.2024			% 5 Tage	% 1. Jan.
1,01 ^USD	-3,81 %		-7,34 %	-18,55 %

09.05.	Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09.05.	Akebia Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.06.
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference	23.05.
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference	14.05.
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M	09.05.
Akebia Therapeutics: Q1 Earnings Snapshot	09.05.
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	09.05.
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights	02.05.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.05.
Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23.04.
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16.04.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03.04.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
Sector Update: Health Care Stocks Advance Premarket Thursday	28.03.
Sector Update: Health Care	28.03.
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	28.03.
Akebia Shares Rally Premarket After FDA Approves Vafseo	28.03.
U.S. FDA approves Akebia's anemia drug	28.03.
U.S. FDA approves Akebia's anemia drug	28.03.
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Akebia Therapeutics, Inc.

Aktien

A1XF0S

US00972D1054

AKBA

Andere Sprachen

Filter